Olmesartanmedoxomil/Amlodipin Viatris (Olmesartan Medoxomil, Amlodipine)

Olmesartanmedoxomil/Amlodipin Viatris is indicated for the treatment of hypertension, acting on the renin‑angiotensin system and vascular smooth‑muscle tone.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Hypertension with high cardiovascular risk: provides additional protection against stroke and myocardial infarction.
• Hypertension in patients requiring combination therapy: simplifies treatment by combining an ARB with a calcium‑channel blocker.

• Olmesartan medoxil blocks the binding of angiotensin II to the AT1 receptor, preventing vasoconstriction and aldosterone release, while amlodipine inhibits calcium influx into vascular smooth‑muscle cells, producing arterial dilation. The combined effect results in reduced peripheral resistance and lower blood pressure.

Adverse reactions may occur with any antihypertensive regimen.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Peripheral edema
• Flushing
• Fatigue
• Nasal congestion

Serious or Rare Side Effects

• Angio‑edema involving the face, lips or tongue
• Severe hypotension
• Acute kidney injury
• Hepatic enzyme elevation
• Myocardial infarction in susceptible patients
• Severe allergic skin reactions (e.g., Stevens‑Johnson syndrome)

Patients should be evaluated for contraindications and monitored during therapy.

• Renal impairment: adjust dose or avoid if severe.
• Hepatic impairment: use with caution; monitor liver function.
• Electrolyte disturbances: check potassium and sodium levels regularly.
• Pregnancy: discontinue if pregnancy is confirmed; risk of fetal toxicity.
• Elderly patients: start at lower dose and monitor for orthostatic hypotension.
• Store at ambient temperature: keep in original packaging, protect from moisture and light.

Olmesartanmedoxomil/Amlodipin Viatris may interact with several drug classes.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): increased risk of renal dysfunction and hyperkalaemia.
• Potassium‑sparing diuretics or supplements: heightened hyperkalaemia risk.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihy‑hypertensive effect and affect renal function.
• CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): can raise amlodipine plasma levels.
• CYP3A4 inducers (e.g., rifampicin): may reduce amlodipine exposure.
• Diuretics: may enhance hypotensive effect, requiring dose adjustment.
• Lithium: monitor serum levels as ARBs can increase lithium retention.